Glenmark Pharmaceuticals on Friday said it has received final approval from the US health regulator for Pimecrolimus Cream, used to treat skin conditions such as eczema.
The approved product is a generic version of Elidel Cream, 1 per cent, of Bausch Health US, LLC.
Glenmark Pharmaceuticals Inc., USA, has been granted final approval by the the United States Food and Drug Administration (USFDA) for Pimecrolimus Cream, 1 per cent, the company said in a BSE filing.
Citing IQVIA sales data, Glenmark said, Elidel Cream achieved annual sales of approximately USD 198.8 million in the 12-month period ended July 2019.
The company said its current portfolio consists of 160 products authorised for distribution in the US and 55 Abbreviated New Drug Application's (ANDA) pending approval with the USFDA.
Shares of Glenmark Pharma were trading 0.22 per cent higher at Rs 384.35 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app